Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
DAPA-HF
2 other identifiers
interventional
4,744
20 countries
419
Brief Summary
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Feb 2017
419 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 26, 2017
CompletedFirst Posted
Study publicly available on registry
January 30, 2017
CompletedStudy Start
First participant enrolled
February 8, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 17, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
July 17, 2019
CompletedResults Posted
Study results publicly available
September 1, 2020
CompletedSeptember 1, 2020
August 1, 2020
2.4 years
January 26, 2017
July 6, 2020
August 31, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
Primary efficacy
Up to 27.8 months.
Secondary Outcomes (5)
Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.
Up to 27.8 months.
Events Included in the Composite Endpoint of Recurrent Hospitalizations Due to Heart Failure and CV Death.
Up to 27.8 months.
Change From Baseline in the KCCQ Total Symptom Score
Baseline and 8 months or death before 8 months
Subjects Included in the Composite Endpoint of ≥50% Sustained Decline in eGFR, ESRD or Renal Death.
Up to 27.8 months.
Subjects Included in the Endpoint of All-cause Mortality.
Up to 27.8 months.
Study Arms (2)
Dapagliflozin
EXPERIMENTALPatients will be randomized 1:1 to either dapagliflozin or placebo.
Placebo
PLACEBO COMPARATORPlacebo matching dapagliflozin.
Interventions
10 mg or 5 mg tablets given once daily, per oral use.
Eligibility Criteria
You may qualify if:
- Provision of signed informed consent prior to any study specific procedures
- Male or female, aged ≥18 years
- Established documented diagnosis of symptomatic HFrEF (NYHA functional class II-IV), which has been present for at least 2 months
- LVEF≤40%
- Elevated NT-proBNP levels
- Patients should receive background standard of care for HFrEF and be treated according to locally recognized guidelines
- eGFR ≥30 mL/min/1.73 m\^2 (CKD-EPI formula) at enrolment (visit 1)
You may not qualify if:
- Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
- Type 1 diabetes mellitus
- Symptomatic hypotension or systolic BP \<95 mmHg at 2 out of 3 measurements either at visit 1 or visit 2
- Current acute decompensated HF or hospitalization due to decompensated HF \<4 weeks prior to enrolment
- MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment
- Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization
- Implantation of a CRT within 12 weeks prior to enrolment or intent to implant a CRT device
- Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization
- HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease
- Symptomatic bradycardia or second or third degree heart block without a pacemaker
- Severe (eGFR \<30 mL/min/1.73 m\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (419)
Research Site
Fairhope, Alabama, 36532, United States
Research Site
Mobile, Alabama, 36608, United States
Research Site
Sheffield, Alabama, 35660, United States
Research Site
Bakersfield, California, 93309, United States
Research Site
Beverly Hills, California, 90211, United States
Research Site
Los Angeles, California, 90073, United States
Research Site
Palm Springs, California, 92262, United States
Research Site
Stockton, California, 95204, United States
Research Site
Torrance, California, 90502, United States
Research Site
Vista, California, 92083, United States
Research Site
Wilmington, Delaware, 19803, United States
Research Site
Boynton Beach, Florida, 33472, United States
Research Site
Jacksonville, Florida, 32209, United States
Research Site
Jacksonville, Florida, 32216, United States
Research Site
Lake Worth, Florida, 33461, United States
Research Site
Miami, Florida, 33125, United States
Research Site
Miami, Florida, 33155, United States
Research Site
Naples, Florida, 34102, United States
Research Site
New Smyrna Beach, Florida, 32169, United States
Research Site
Pembroke Pines, Florida, 33024, United States
Research Site
Port Charlotte, Florida, 33952, United States
Research Site
Saint Augustine, Florida, 32086, United States
Research Site
Wellington, Florida, 33449, United States
Research Site
Atlanta, Georgia, 30303, United States
Research Site
Cumming, Georgia, 30041, United States
Research Site
Tucker, Georgia, 30084, United States
Research Site
Hazel Crest, Illinois, 60429, United States
Research Site
Jerseyville, Illinois, 62052, United States
Research Site
Peoria, Illinois, 61614, United States
Research Site
Louisville, Kentucky, 40205, United States
Research Site
Alexandria, Louisiana, 71301, United States
Research Site
Chalmette, Louisiana, 70043, United States
Research Site
Bangor, Maine, 04401, United States
Research Site
Baltimore, Maryland, 21120, United States
Research Site
Baltimore, Maryland, 21228, United States
Research Site
Columbia, Maryland, 21044, United States
Research Site
Boston, Massachusetts, 02114, United States
Research Site
Haverhill, Massachusetts, 01830, United States
Research Site
Flint, Michigan, 48504, United States
Research Site
Flint, Michigan, 48532, United States
Research Site
Lansing, Michigan, 48910, United States
Research Site
Minneapolis, Minnesota, 55407, United States
Research Site
Minneapolis, Minnesota, 55417, United States
Research Site
Tupelo, Mississippi, 38801, United States
Research Site
Kansas City, Missouri, 64111, United States
Research Site
St Louis, Missouri, 63128, United States
Research Site
Great Falls, Montana, 59405, United States
Research Site
Grand Island, Nebraska, 68803, United States
Research Site
Lincoln, Nebraska, 68526, United States
Research Site
Omaha, Nebraska, 68105, United States
Research Site
Las Vegas, Nevada, 89128, United States
Research Site
Bridgewater, New Jersey, 08807, United States
Research Site
New Brunswick, New Jersey, 08901, United States
Research Site
Somerset, New Jersey, 08873, United States
Research Site
Buffalo, New York, 14203, United States
Research Site
Buffalo, New York, 14215, United States
Research Site
Cortlandt Manor, New York, 10567, United States
Research Site
New York, New York, 10001, United States
Research Site
Orchard Park, New York, 14127, United States
Research Site
Poughkeepsie, New York, 12601, United States
Research Site
Rosedale, New York, 11422, United States
Research Site
The Bronx, New York, 10459, United States
Research Site
Burlington, North Carolina, 27215, United States
Research Site
Cleveland, Ohio, 44106-6010, United States
Research Site
Columbus, Ohio, 43210, United States
Research Site
Altoona, Pennsylvania, 16602, United States
Research Site
Philadelphia, Pennsylvania, 19104, United States
Research Site
Pittsburgh, Pennsylvania, 15212, United States
Research Site
Pittsburgh, Pennsylvania, 15240, United States
Research Site
Rapid City, South Dakota, 57701, United States
Research Site
Knoxville, Tennessee, 37912, United States
Research Site
Memphis, Tennessee, 38104, United States
Research Site
Nashville, Tennessee, 37212, United States
Research Site
Tullahoma, Tennessee, 37388, United States
Research Site
Beaumont, Texas, 77702, United States
Research Site
Dallas, Texas, 75231, United States
Research Site
Dallas, Texas, 75246, United States
Research Site
Houston, Texas, 77002, United States
Research Site
Kingwood, Texas, 77339, United States
Research Site
San Antonio, Texas, 78234, United States
Research Site
Tyler, Texas, 75701, United States
Research Site
Farmington, Utah, 84025, United States
Research Site
Falls Church, Virginia, 22042, United States
Research Site
Richmond, Virginia, 23298, United States
Research Site
Seattle, Washington, 98101, United States
Research Site
Seattle, Washington, 98195, United States
Research Site
Buenos Aires, C1180AAX, Argentina
Research Site
Buenos Aires, C1425AGC, Argentina
Research Site
CABA, 1428, Argentina
Research Site
CABA, 1437, Argentina
Research Site
CABA, C1119ACN, Argentina
Research Site
CABA, C1120AAC, Argentina
Research Site
Caba, C1425DQI, Argentina
Research Site
Ciudad Autonoma Buenos Aires, 1093, Argentina
Research Site
Ciudad Autonoma de Buenos Aire, C1407GTN, Argentina
Research Site
Ciudad de Buenos Aires, 1221, Argentina
Research Site
Corrientes, W3400AMZ, Argentina
Research Site
Córdoba, 5003, Argentina
Research Site
Córdoba, X5004BAL, Argentina
Research Site
Córdoba, X5006CBI, Argentina
Research Site
Esperanza, S3080BQU, Argentina
Research Site
Mar del Plata, 7600, Argentina
Research Site
Mar del Plata, B7600FZN, Argentina
Research Site
Quilmes, B1878DVB, Argentina
Research Site
Quilmes, B1878GEG, Argentina
Research Site
Ramos Mejía, B1704ETD, Argentina
Research Site
Rosario, 2000, Argentina
Research Site
Rosario, S2000CVD, Argentina
Research Site
San Luis, 5700, Argentina
Research Site
San Martín, 1650, Argentina
Research Site
San Miguel de Tucumán, 4000, Argentina
Research Site
San Nicolás, B2900DMH, Argentina
Research Site
Santa Fe, S3000FWO, Argentina
Research Site
Vicente López, 1638, Argentina
Research Site
Belo Horizonte, 30140 062, Brazil
Research Site
Belo Horizonte, 30150-240, Brazil
Research Site
Brasillia, 70200-730, Brazil
Research Site
Brasília, 71625-175, Brazil
Research Site
Campina Grande do Sul, 83430000, Brazil
Research Site
Campinas, 13060-080, Brazil
Research Site
Curitiba, 80730-150, Brazil
Research Site
Goiânia, 74605050, Brazil
Research Site
Marília, 17515-000, Brazil
Research Site
Porto Alegre, 90020-090, Brazil
Research Site
Porto Alegre, 90035-903, Brazil
Research Site
Porto Alegre, 90620-001, Brazil
Research Site
Porto Alegre, 90840-440, Brazil
Research Site
Porto Alegre, 91350-200, Brazil
Research Site
Rio de Janeiro, 22271-100, Brazil
Research Site
São José do Rio Preto, 15090-000, Brazil
Research Site
São Paulo, 05403-000, Brazil
Research Site
Uberlândia, 38411-186, Brazil
Research Site
Votuporanga, 15500-003, Brazil
Research Site
Blagoevgrad, 2700, Bulgaria
Research Site
Dimitrovgrad, 6400, Bulgaria
Research Site
Haskovo, Bulgaria
Research Site
Kyustendil, 2500, Bulgaria
Research Site
Lom, 3600, Bulgaria
Research Site
Pleven, 5800, Bulgaria
Research Site
Plovdiv, 4000, Bulgaria
Research Site
Plovdiv, 4001, Bulgaria
Research Site
Plovdiv, 4002, Bulgaria
Research Site
Plovdiv, 4003, Bulgaria
Research Site
Sofia, 1309, Bulgaria
Research Site
Sofia, 1408, Bulgaria
Research Site
Sofia, 1431, Bulgaria
Research Site
Sofia, 1463, Bulgaria
Research Site
Sofia, 1527, Bulgaria
Research Site
Sofia, 1606, Bulgaria
Research Site
Sofia, 1750, Bulgaria
Research Site
Calgary, Alberta, T2N 4Z6, Canada
Research Site
Abbotsford, British Columbia, V2S 3N2, Canada
Research Site
New Westminster, British Columbia, V3L 3W4, Canada
Research Site
North Vancouver, British Columbia, V7M 2H4, Canada
Research Site
Moncton, New Brunswick, E1C 2Z3, Canada
Research Site
Saint John, New Brunswick, E2L 4L2, Canada
Research Site
Brampton, Ontario, L6W 2X7, Canada
Research Site
Cambridge, Ontario, N1R 6V6, Canada
Research Site
Cambridge, Ontario, N1R 7R1, Canada
Research Site
Hamilton, Ontario, L8L 2X2, Canada
Research Site
London, Ontario, N6A 5A5, Canada
Research Site
Newmarket, Ontario, L3Y 2P6, Canada
Research Site
North York, Ontario, M6B 3H7, Canada
Research Site
Oakville, Ontario, L6K 3W7, Canada
Research Site
Oshawa, Ontario, L1J 2K1, Canada
Research Site
Peterborough, Ontario, K9J 0B2, Canada
Research Site
Port Perry, Ontario, L9L 1L1, Canada
Research Site
Scarborough Village, Ontario, M1B 4Z8, Canada
Research Site
Scarborough Village, Ontario, M1E 5E9, Canada
Research Site
Waterloo, Ontario, N2T 0C1, Canada
Research Site
York, Ontario, M9N 1W4, Canada
Research Site
Greenfield Park, Quebec, J4V 2G8, Canada
Research Site
Montreal, Quebec, H1T 1C8, Canada
Research Site
Montreal, Quebec, H1T 3Y7, Canada
Research Site
Montreal, Quebec, H2X 0A9, Canada
Research Site
Québec, Quebec, G1V 4G5, Canada
Research Site
Rimouski, Quebec, G5L 5T1, Canada
Research Site
Saint-Jérôme, Quebec, J7Z 5T3, Canada
Research Site
Terrebonne, Quebec, J6V 2H2, Canada
Research Site
Baotou, 014010, China
Research Site
Beijing, 100029, China
Research Site
Beijing, China
Research Site
Bengbu, 233060, China
Research Site
Changchun, 130021, China
Research Site
Changsha, 410011, China
Research Site
Chifeng, 024000, China
Research Site
Dalian, 116011, China
Research Site
Guangzhou, 510080, China
Research Site
Haerbin, 150001, China
Research Site
Lanzhou, 730030, China
Research Site
Nanchang, 330006, China
Research Site
Nanjing, 210009, China
Research Site
Nanjing, 210029, China
Research Site
Ningbo, 315010, China
Research Site
Pingxiang, 337055, China
Research Site
Shanghai, 200025, China
Research Site
Shanghai, 200032, China
Research Site
Shanghai, 200062, China
Research Site
Shanghai, 200090, China
Research Site
Shanghai, 200120, China
Research Site
Shenyang, 110001, China
Research Site
Shenzhen, 518036, China
Research Site
Tianjin, 300211, China
Research Site
Wuhan, 430033, China
Research Site
Wuhan, 430060, China
Research Site
Xuzhou, 221006, China
Research Site
Xuzhou, 221009, China
Research Site
Yinchuan, 750004, China
Research Site
Zhuhai, 519000, China
Research Site
Benešov, 256 01, Czechia
Research Site
Brno, 62500, Czechia
Research Site
Brno, 656 91, Czechia
Research Site
Kolín, 280 00, Czechia
Research Site
Louny, 440 01, Czechia
Research Site
Ostrava-Dubina, 700 30, Czechia
Research Site
Pilsen, 320 00, Czechia
Research Site
Prague, 12808, Czechia
Research Site
Prague, 140 00, Czechia
Research Site
Prague, 140 59, Czechia
Research Site
Prague, 150 00, Czechia
Research Site
Třebíč, 674 01, Czechia
Research Site
Hellerup, 2900, Denmark
Research Site
Herlev, 2730, Denmark
Research Site
Hvidovre, 2650, Denmark
Research Site
København Ø, 2100, Denmark
Research Site
Odense C, 5000, Denmark
Research Site
Svendborg, DK-5700, Denmark
Research Site
Bad Oeynhausen, 32545, Germany
Research Site
Berlin, 13347, Germany
Research Site
Berlin, 13597, Germany
Research Site
Dresden, 01099, Germany
Research Site
Dresden, 01307, Germany
Research Site
Hamburg, 22041, Germany
Research Site
Homburg, 66424, Germany
Research Site
Kassel, 34121, Germany
Research Site
Leipzig, 04107, Germany
Research Site
Mainz, 55131, Germany
Research Site
Papenburg, 26871, Germany
Research Site
Stuttgart, 70199, Germany
Research Site
Wermsdorf, 04779, Germany
Research Site
Budapest, 1115, Hungary
Research Site
Budapest, 1122, Hungary
Research Site
Budapest, 1135, Hungary
Research Site
Budapest, 1139, Hungary
Research Site
Budapest, H-1106, Hungary
Research Site
Kecskemét, 6000, Hungary
Research Site
Mosonmagyaróvár, 9200, Hungary
Research Site
Szentes, 6600, Hungary
Research Site
Székesfehérvár, 8000, Hungary
Research Site
Zalaegerszeg, 8900, Hungary
Research Site
Ahmedabad, 380060, India
Research Site
Aurangabad, 431003, India
Research Site
Bangalore, 560074, India
Research Site
Belagavi, 590010, India
Research Site
Ernākulam, 683594, India
Research Site
Gūrgaon, 122001, India
Research Site
Kanpur, 208002, India
Research Site
Karamsad, 388345, India
Research Site
Kolkata, 700020, India
Research Site
Maharashtra, 411013, India
Research Site
Nadiād, 387002, India
Research Site
Nagpur, 420012, India
Research Site
Nagpur, 440003, India
Research Site
New Delhi, 110002, India
Research Site
Pune, 411001, India
Research Site
Pune, 411011, India
Research Site
Adachi-ku, 123-0845, Japan
Research Site
Aki-gun,, 735-8585, Japan
Research Site
Azumino-shi, 399-8292, Japan
Research Site
Beppu-shi, 874-0011, Japan
Research Site
Bunkyō City, 113-8431, Japan
Research Site
Chikushino-shi, 818-8516, Japan
Research Site
Chūōku, 103-0027, Japan
Research Site
Chūōku, 104-8560, Japan
Research Site
Fujisawa-shi, 251-0041, Japan
Research Site
Fujisawa-shi, 251-8550, Japan
Research Site
Fukuoka, 815-8555, Japan
Research Site
Hachioji-shi, 192-0918, Japan
Research Site
Hamamatsu, 430-0929, Japan
Research Site
Himeji-shi, 670-0981, Japan
Research Site
Hiratsuka-shi, 254-8502, Japan
Research Site
Hitachi-Naka, 312-0057, Japan
Research Site
Iizuka-shi, 820-8505, Japan
Research Site
Itabashi-ku, 173-8610, Japan
Research Site
Iwakuni-shi, 740-8510, Japan
Research Site
Kagoshima, 890-8520, Japan
Research Site
Kakamigahara-shi, 504-8601, Japan
Research Site
Kasama-shi, 309-1793, Japan
Research Site
Kishiwada-shi, 596-8522, Japan
Research Site
Kitakyusyu-shi, 806-8501, Japan
Research Site
Kumamoto, 860-0008, Japan
Research Site
Kure-shi, 737-0023, Japan
Research Site
Kusatsu-shi, 525-8585, Japan
Research Site
Kyoto, 601-1434, Japan
Research Site
Matsudo-shi, 270-2251, Japan
Research Site
Matsudo-shi, 271-0077, Japan
Research Site
Matsumoto-shi, 390-8621, Japan
Research Site
Matsuyama, 790-0067, Japan
Research Site
Meguro-ku, 152-8902, Japan
Research Site
Mito, 311-4198, Japan
Research Site
Miura-gun, 240-0116, Japan
Research Site
Nagasaki, 850-8555, Japan
Research Site
Nagoya, 453-8511, Japan
Research Site
Nagoya, 455-8530, Japan
Research Site
Nagoya, 457-8511, Japan
Research Site
Nagoya, 460-0001, Japan
Research Site
Nishinomiya-shi, 663-8501, Japan
Research Site
Okayama, 700-0804, Japan
Research Site
Osaka, 530-0001, Japan
Research Site
Osaka, 540-0006, Japan
Research Site
Sagamihara-shi, 252-5188, Japan
Research Site
Sakai-shi,Kita-ku, 591-8025, Japan
Research Site
Sakaide-shi, 762-0007, Japan
Research Site
Sanyoonoda-shi, 756-0095, Japan
Research Site
Sayama-shi, 350-1305, Japan
Research Site
Sendai, 980-0803, Japan
Research Site
Sendai, 983-0045, Japan
Research Site
Shimonoseki-shi, 750-0061, Japan
Research Site
Shinjuku-ku, 169-0073, Japan
Research Site
Suita-shi, 564-8565, Japan
Research Site
Suwa-shi, 392-8510, Japan
Research Site
Tachikawa-shi, 190-8531, Japan
Research Site
Takamatsu, 760-0018, Japan
Research Site
Takasaki-shi, 370-0829, Japan
Research Site
Toride-shi, 302-0022, Japan
Research Site
Tsuchiura-shi, 300-0028, Japan
Research Site
Tsukuba, 305-0005, Japan
Research Site
Ueda-shi, 386-8610, Japan
Research Site
Wakayama, 640-8505, Japan
Research Site
Wakayama, 649-6335, Japan
Research Site
Wako-shi, 351-0102, Japan
Research Site
Yokohama, 236-0051, Japan
Research Site
's-Hertogenbosch, 5223 GZ, Netherlands
Research Site
Apeldoorn, 7334 DZ, Netherlands
Research Site
Gouda, 2803 HH, Netherlands
Research Site
Groningen, 9713 GZ, Netherlands
Research Site
Nijmegen, 6525 GA, Netherlands
Research Site
Rotterdam, 3045 PM, Netherlands
Research Site
Rotterdam, 3083 AN, Netherlands
Research Site
Sneek, 8601 ZR, Netherlands
Research Site
The Hague, 2545 AA, Netherlands
Research Site
Veldhoven, 5504 DB, Netherlands
Research Site
Bochnia, 32-700, Poland
Research Site
Gdynia, 81-423, Poland
Research Site
Jasło, 38-200, Poland
Research Site
Katowice, 40-081, Poland
Research Site
Kędzierzyn-Koźle, 47-200, Poland
Research Site
Krakow, 30-082, Poland
Research Site
Legnica, 59-220, Poland
Research Site
Lodz, 92-213, Poland
Research Site
Lublin, 20-044, Poland
Research Site
Oława, 55-200, Poland
Research Site
Płock, 09-402, Poland
Research Site
Sokółka, 16-100, Poland
Research Site
Torun, 87-100, Poland
Research Site
Wierzchosławice, 33-122, Poland
Research Site
Gatchina, 188300, Russia
Research Site
Izhevsk, 426063, Russia
Research Site
Kazan', 420012, Russia
Research Site
Moscow, 109263, Russia
Research Site
Moscow, 119435, Russia
Research Site
Moscow, 121551, Russia
Research Site
Moscow, 121552, Russia
Research Site
Novosibirsk, 630055, Russia
Research Site
Perm, 6144090, Russia
Research Site
Ryazan, 390039, Russia
Research Site
Saint Petersburg, 192283, Russia
Research Site
Saint Petersburg, 194291, Russia
Research Site
Saint Petersburg, 194354, Russia
Research Site
Saint Petersburg, 195067, Russia
Research Site
Saint Petersburg, 196084, Russia
Research Site
Saint Petersburg, 196601, Russia
Research Site
Saint Petersburg, 198260, Russia
Research Site
Tver', 170036, Russia
Research Site
Yekaterinburg, 620039, Russia
Research Site
Yekaterinburg, 620102, Russia
Research Site
Brezno, 97742, Slovakia
Research Site
Košice, 040 01, Slovakia
Research Site
Lučenec, 984 01, Slovakia
Research Site
Martin, 036 01, Slovakia
Research Site
Nové Zámky, 94001, Slovakia
Research Site
Prešov, 080 01, Slovakia
Research Site
Svidník, 08901, Slovakia
Research Site
Trebišov, 075 01, Slovakia
Research Site
Trnava, 917 01, Slovakia
Research Site
Žilina, 010 01, Slovakia
Research Site
Gothenburg, 413 45, Sweden
Research Site
Lund, 222 21, Sweden
Research Site
Östersund, 831 83, Sweden
Research Site
Stockholm, 118 83, Sweden
Research Site
Umeå, 90737, Sweden
Research Site
Changhua, 50006, Taiwan
Research Site
Hsinchu, 300, Taiwan
Research Site
Kaohsiung City, 80756, Taiwan
Research Site
Kaohsiung City, Taiwan
Research Site
Kweishan Shiang, 333, Taiwan
Research Site
Taichung, 40705, Taiwan
Research Site
Taichung, Taiwan
Research Site
Tainan, 70403, Taiwan
Research Site
Tainan, 710, Taiwan
Research Site
Taipei, 11217, Taiwan
Research Site
Taipei, 11220, Taiwan
Research Site
Taipei, Taiwan
Research Site
Airdrie, ML6 0JS, United Kingdom
Research Site
Clydebank, G81 4DY, United Kingdom
Research Site
Cottingham, HU16 5JQ, United Kingdom
Research Site
Dundee, DD1 9SY, United Kingdom
Research Site
Edinburgh, EH16 4SA, United Kingdom
Research Site
Glasgow, G31 2ER, United Kingdom
Research Site
Glasgow, G51 4TF, United Kingdom
Research Site
Inverness, IV2 3JH, United Kingdom
Research Site
Nottingham, NG5 1PB, United Kingdom
Research Site
Paisley, PA2 9PN, United Kingdom
Research Site
Hanoi, 100000, Vietnam
Research Site
Hanoi, Vietnam
Research Site
Ho Chi Minh City, 7000000, Vietnam
Research Site
Ho Chi Minh City, 700000, Vietnam
Research Site
Ho Chi Minh City, 70000, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Related Publications (52)
Myte R, Mattsson A, Poole M, Little DJ, Nystrom P, Henderson A, Claggett BL, Gasparyan SB, Solomon SD, McMurray JJV. Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin. Circ Heart Fail. 2025 Dec;18(12):e013496. doi: 10.1161/CIRCHEARTFAILURE.125.013496. Epub 2025 Oct 31.
PMID: 41170566DERIVEDMcDowell K, Welsh P, Docherty KF, Morrow DA, Jhund PS, De Boer RA, O'Meara E, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Hammarstedt A, Langkilde AM, Solomon SD, Sattar N, Sabatine MS, McMurray JJV. Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical Trial. JAMA Cardiol. 2025 Aug 1;10(8):797-808. doi: 10.1001/jamacardio.2025.1592.
PMID: 40465275DERIVEDDocherty KF, McDowell K, Welsh P, Petrie MC, Anand I, Berg DD, de Boer RA, Kober L, Kosiborod MN, Martinez FA, O'Meara E, Morrow DA, Ponikowski P, Sabatine MS, Sattar N, Schou M, Hammarstedt A, Sjostrand M, Langkilde AM, Jhund PS, Solomon SD, McMurray JJV. Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. JACC Heart Fail. 2025 Jul;13(7):102393. doi: 10.1016/j.jchf.2024.12.012. Epub 2025 Mar 12.
PMID: 40088234DERIVEDNatale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
PMID: 38770818DERIVEDKondo T, Mogensen UM, Talebi A, Gasparyan SB, Campbell RT, Docherty KF, de Boer RA, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Sabatine MS, Bengtsson O, Sjostrand M, Vaduganathan M, Solomon SD, Jhund PS, McMurray JJV. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. J Am Coll Cardiol. 2024 May 21;83(20):1973-1986. doi: 10.1016/j.jacc.2024.03.385. Epub 2024 Mar 25.
PMID: 38537918DERIVEDKondo T, Gasparyan SB, Jhund PS, Bengtsson O, Claggett BL, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Kober L, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Ponikowski P, Sabatine MS, Shah SJ, Sjostrand M, Wilderang U, Vaduganathan M, Solomon SD, McMurray JJV. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. NEJM Evid. 2023 Nov;2(11):EVIDoa2300042. doi: 10.1056/EVIDoa2300042. Epub 2023 Oct 24.
PMID: 38320525DERIVEDKondo T, Butt JH, Curtain JP, Jhund PS, Docherty KF, Claggett BL, Vaduganathan M, Bachus E, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Kober L, Ponikowski P, Sabatine MS, Solomon SD, McMurray JJV. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circ Heart Fail. 2023 Dec;16(12):e010898. doi: 10.1161/CIRCHEARTFAILURE.123.010898. Epub 2023 Oct 27.
PMID: 37886880DERIVEDDocherty KF, McDowell K, Welsh P, Osmanska J, Anand I, de Boer RA, Kober L, Kosiborod MN, Martinez FA, O'Meara E, Ponikowski P, Schou M, Berg DD, Sabatine MS, Morrow DA, Jarolim P, Hammarstedt A, Sjostrand M, Langkilde AM, Solomon SD, Sattar N, Jhund PS, McMurray JJV. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure. J Am Coll Cardiol. 2023 Jul 11;82(2):142-157. doi: 10.1016/j.jacc.2023.05.011.
PMID: 37407113DERIVEDButt JH, Docherty KF, Kosiborod MN, Inzucchi SE, Kober L, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjostrand M, Solomon S, Jhund PS, McMurray JJV. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2023 Oct;11(10):1411-1423. doi: 10.1016/j.jchf.2023.04.016. Epub 2023 Jun 14.
PMID: 37318419DERIVEDButt JH, Kondo T, Yang M, Jhund PS, Docherty KF, Vaduganathan M, Claggett BL, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Kober L, Ponikowski P, Sabatine MS, Shah SJ, Zaozerska N, Wilderang U, Bengtsson O, Solomon SD, McMurray JJV. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023 Jun 25;44(24):2170-2183. doi: 10.1093/eurheartj/ehad276.
PMID: 37220172DERIVEDBhatt AS, Kosiborod MN, Vaduganathan M, Claggett BL, Miao ZM, Kulac IJ, Lam CSP, Hernandez AF, Martinez F, Inzucchi SE, Shah SJ, de Boer RA, Jhund PS, Desai AS, Petersson M, Langkilde AM, McMurray JJV, Solomon SD. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials. Eur J Heart Fail. 2023 Jul;25(7):981-988. doi: 10.1002/ejhf.2909. Epub 2023 Jun 7.
PMID: 37211977DERIVEDChatur S, Kondo T, Claggett BL, Docherty K, Miao ZM, Desai AS, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD, Vaduganathan M. Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HF. Eur J Heart Fail. 2023 Aug;25(8):1364-1371. doi: 10.1002/ejhf.2912. Epub 2023 Jun 8.
PMID: 37210608DERIVEDYeoh SE, Docherty KF, Campbell RT, Jhund PS, Hammarstedt A, Heerspink HJL, Jarolim P, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Solomon SD, Sjostrand M, Bengtsson O, Greasley PJ, Sattar N, Welsh P, Sabatine MS, Morrow DA, McMurray JJV. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. Circulation. 2023 May 30;147(22):1670-1683. doi: 10.1161/CIRCULATIONAHA.122.063327. Epub 2023 Apr 11.
PMID: 37039015DERIVEDButt JH, Docherty KF, Claggett BL, Desai AS, Fang JC, Petersson M, Langkilde AM, de Boer RA, Cabrera Honorio JW, Hernandez AF, Inzucchi SE, Kosiborod MN, Kober L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Vardeny O, O'Meara E, Saraiva JFK, Shah SJ, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. JACC Heart Fail. 2023 Apr;11(4):375-388. doi: 10.1016/j.jchf.2022.11.014. Epub 2023 Feb 1.
PMID: 36881399DERIVEDButt JH, Docherty KF, Claggett BL, Desai AS, Petersson M, Langkilde AM, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Kober L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Shah SJ, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2023 Apr 1;8(4):386-393. doi: 10.1001/jamacardio.2022.5608.
PMID: 36811901DERIVEDAdamson C, Welsh P, Docherty KF, de Boer RA, Diez M, Drozdz J, Dukat A, Inzucchi SE, Kober L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Lindholm D, Hammarstedt A, Boulton DW, Greasley PJ, Langkilde AM, Solomon SD, Sattar N, McMurray JJV, Jhund PS. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. JACC Heart Fail. 2023 Mar;11(3):291-304. doi: 10.1016/j.jchf.2022.09.004. Epub 2022 Nov 9.
PMID: 36592046DERIVEDDocherty KF, Anand IS, Chiang CE, Chopra VK, Desai AS, Kitakaze M, Verma S, Vinh PN, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJV. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia. 2022 Mar 29;2(2):139-153. doi: 10.1016/j.jacasi.2022.02.004. eCollection 2022 Apr.
PMID: 36339117DERIVEDDesai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, Barkoudah E, Brahimi A, Connolly E, Finn P, Lang NN, Mc Causland FR, McGrath M, Petrie MC, McMurray JJV, Solomon SD. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022 Dec 1;7(12):1227-1234. doi: 10.1001/jamacardio.2022.3736.
PMID: 36189985DERIVEDAdamson C, Cowan LM, de Boer RA, Diez M, Drozdz J, Dukat A, Inzucchi SE, Kober L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Lindholm D, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjostrand M, Solomon SD, McMurray JJV, Jhund PS. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. Eur J Heart Fail. 2022 Oct;24(10):1856-1868. doi: 10.1002/ejhf.2649. Epub 2022 Aug 22.
PMID: 36054568DERIVEDDocherty KF, Welsh P, Verma S, De Boer RA, O'Meara E, Bengtsson O, Kober L, Kosiborod MN, Hammarstedt A, Langkilde AM, Lindholm D, Little DJ, Sjostrand M, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Schou M, Solomon SD, Sattar N, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation. 2022 Sep 27;146(13):980-994. doi: 10.1161/CIRCULATIONAHA.122.060511. Epub 2022 Aug 16.
PMID: 35971840DERIVEDButt JH, Dewan P, DeFilippis EM, Biering-Sorensen T, Docherty KF, Jhund PS, Kosiborod MN, Martinez FA, Bengtsson O, Johansen ND, Langkilde AM, Sjostrand M, Vaduganathan M, Solomon SD, Sabatine MS, Kober L, Fiuzat M, McMurray JJV. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. JACC Heart Fail. 2022 Aug;10(8):543-555. doi: 10.1016/j.jchf.2022.03.009. Epub 2022 Jun 8.
PMID: 35902157DERIVEDYeoh SE, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjostrand M, Solomon SD, McMurray JJV. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial. JACC Heart Fail. 2022 May;10(5):306-318. doi: 10.1016/j.jchf.2022.01.019. Epub 2022 Apr 6.
PMID: 35483792DERIVEDButt JH, Dewan P, Merkely B, Belohlavek J, Drozdz J, Kitakaze M, Inzucchi SE, Kosiborod MN, Martinez FA, Tereshchenko S, Ponikowski P, Bengtsson O, Lindholm D, Langkilde AM, Schou M, Sjostrand M, Solomon SD, Sabatine MS, Chiang CE, Docherty KF, Jhund PS, Kober L, McMurray JJV. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. Ann Intern Med. 2022 Jun;175(6):820-830. doi: 10.7326/M21-4776. Epub 2022 Apr 26.
PMID: 35467935DERIVEDAdamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Solomon SD, Verma S, Bengtsson O, Langkilde AM, Sjostrand M, Vaduganathan M, Jhund PS, McMurray JJV. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation. 2022 Aug 9;146(6):438-449. doi: 10.1161/CIRCULATIONAHA.121.058910. Epub 2022 Apr 20.
PMID: 35442064DERIVEDDocherty KF, Simpson J, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Sjostrand M, Lindholm D, Langkilde AM, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. JACC Heart Fail. 2022 Feb;10(2):104-118. doi: 10.1016/j.jchf.2021.09.002. Epub 2022 Jan 12.
PMID: 35115084DERIVEDDocherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'Meara E, Verma S, Inzucchi SE, Kober L, Kosiborod MN, Lindholm D, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJV. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2022 Jan;10(1):52-64. doi: 10.1016/j.jchf.2021.08.006. Epub 2021 Nov 10.
PMID: 34969498DERIVEDRyden L, Ferrannini G. Is the impact of add on heart failure therapy influenced by background therapy? Lancet Diabetes Endocrinol. 2022 Jan;10(1):3-5. doi: 10.1016/S2213-8587(21)00311-9. Epub 2021 Nov 30. No abstract available.
PMID: 34861151DERIVEDButt JH, Adamson C, Docherty KF, de Boer RA, Petrie MC, Inzucchi SE, Kosiborod MN, Maria Langkilde A, Lindholm D, Martinez FA, Bengtsson O, Schou M, O'Meara E, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Jhund PS, McMurray JJV, Kober L. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circ Heart Fail. 2021 Dec;14(12):e008837. doi: 10.1161/CIRCHEARTFAILURE.121.008837. Epub 2021 Nov 22.
PMID: 34802253DERIVEDBerg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, de Boer RA, Kosiborod MN, Nicolau JC, O'Meara E, Schou M, Hammarstedt A, Langkilde AM, Lindholm D, Sjostrand M, McMurray JJV, Sabatine MS, Morrow DA. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation. 2022 Jan 18;145(3):158-169. doi: 10.1161/CIRCULATIONAHA.121.057852. Epub 2021 Nov 8.
PMID: 34743554DERIVEDCurtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjostrand M, Solomon SD, McMurray JJV. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021 Sep 21;42(36):3727-3738. doi: 10.1093/eurheartj/ehab560.
PMID: 34448003DERIVEDDocherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021 Nov 1;6(11):1298-1305. doi: 10.1001/jamacardio.2021.2632.
PMID: 34319398DERIVEDAdamson C, Jhund PS, Docherty KF, Belohlavek J, Chiang CE, Diez M, Drozdz J, Dukat A, Howlett J, Ljungman CEA, Petrie MC, Schou M, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Langkilde AM, Lindholm D, Sjostrand M, McMurray JJV. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. 2021 Oct;23(10):1662-1672. doi: 10.1002/ejhf.2308. Epub 2021 Jul 29.
PMID: 34272791DERIVEDJhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Bohm M, Chiang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjostrand M, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJV. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021 May 18;143(20):1962-1972. doi: 10.1161/CIRCULATIONAHA.121.053659. Epub 2021 Apr 9.
PMID: 33832352DERIVEDButt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O'Meara E, Katova T, Ljungman CEA, Diez M, Ogunniyi MO, Langkilde AM, Sjostrand M, Lindholm D, Bengtsson O, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Jhund PS, McMurray JJV, Kober L. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. JAMA Cardiol. 2021 Jun 1;6(6):678-689. doi: 10.1001/jamacardio.2021.0379.
PMID: 33787831DERIVEDBerg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sjostrand M, Solomon SD, McMurray JJV, Sabatine MS. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021 May 1;6(5):499-507. doi: 10.1001/jamacardio.2020.7585.
PMID: 33595593DERIVEDShen L, Kristensen SL, Bengtsson O, Bohm M, de Boer RA, Docherty KF, Inzucchi SE, Katova T, Kober L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez MFA, O'Meara E, Nicolau JC, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjostrand M, Solomon SD, Jhund PS, McMurray JJV. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. JACC Heart Fail. 2021 Apr;9(4):254-264. doi: 10.1016/j.jchf.2020.11.009. Epub 2021 Feb 3.
PMID: 33549554DERIVEDDewan P, Docherty KF, Bengtsson O, de Boer RA, Desai AS, Drozdz J, Hawkins NM, Inzucchi SE, Kitakaze M, Kober L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjostrand M, Solomon SD, Verma S, Jhund PS, McMurray JJV. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. Eur J Heart Fail. 2021 Apr;23(4):632-643. doi: 10.1002/ejhf.2083. Epub 2021 Jan 18.
PMID: 33368858DERIVEDInzucchi SE, Docherty KF, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Verma S, Belohlavek J, Bohm M, Chiang CE, de Boer RA, Diez M, Dukat A, Ljungman CEA, Bengtsson O, Langkilde AM, Sjostrand M, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. 2021 Feb;44(2):586-594. doi: 10.2337/dc20-1675. Epub 2020 Dec 18.
PMID: 33355302DERIVEDYeoh SE, Dewan P, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Sjostrand M, Langkilde AM, McMurray JJV; DAPA-HF Investigators and Committees. Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy? Circ Heart Fail. 2020 Dec;13(12):e007879. doi: 10.1161/CIRCHEARTFAILURE.120.007879. Epub 2020 Nov 9.
PMID: 33164553DERIVEDDocherty KF, Jhund PS, Bengtsson O, DeMets DL, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Sabatine MS, Sjostrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care. 2020 Nov;43(11):2878-2881. doi: 10.2337/dc20-1402. Epub 2020 Sep 2.
PMID: 33082245DERIVEDJhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Bohm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjostrand M, McMurray JJV. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2021 Jan 26;143(4):298-309. doi: 10.1161/CIRCULATIONAHA.120.050391. Epub 2020 Oct 12.
PMID: 33040613DERIVEDDocherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, de Boer RA, DeMets DL, Desai AS, Drozdz J, Howlett J, Inzucchi SE, Johanson P, Katova T, Kober L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Nicolau JC, O'Meara E, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Tereshchenko S, Verma S, McMurray JJV. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation. 2020 Oct 27;142(17):1623-1632. doi: 10.1161/CIRCULATIONAHA.120.047480. Epub 2020 Sep 4.
PMID: 32883108DERIVEDSerenelli M, Bohm M, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sjostrand M, Langkilde AM, Anand IS, Chiang CE, Chopra VK, de Boer RA, Diez M, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Verma S, Docherty KF, Jhund PS, McMurray JJV. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J. 2020 Sep 21;41(36):3402-3418. doi: 10.1093/eurheartj/ehaa496.
PMID: 32820334DERIVEDJackson AM, Dewan P, Anand IS, Belohlavek J, Bengtsson O, de Boer RA, Bohm M, Boulton DW, Chopra VK, DeMets DL, Docherty KF, Dukat A, Greasley PJ, Howlett JG, Inzucchi SE, Katova T, Kober L, Kosiborod MN, Langkilde AM, Lindholm D, Ljungman CEA, Martinez FA, O'Meara E, Sabatine MS, Sjostrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation. 2020 Sep 15;142(11):1040-1054. doi: 10.1161/CIRCULATIONAHA.120.047077. Epub 2020 Jul 16.
PMID: 32673497DERIVEDSolomon SD, Jhund PS, Claggett BL, Dewan P, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Inzucchi SE, Desai AS, Bengtsson O, Lindholm D, Sjostrand M, Langkilde AM, McMurray JJV. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. JACC Heart Fail. 2020 Oct;8(10):811-818. doi: 10.1016/j.jchf.2020.04.008. Epub 2020 Jul 8.
PMID: 32653447DERIVEDDewan P, Solomon SD, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjostrand M, Langkilde AM, Anand IS, Belohlavek J, Chopra VK, Dukat A, Kitakaze M, Merkely B, O'Meara E, Schou M, Vinh PN, McMurray JJV; DAPA-HF Investigators and Committees. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. Eur J Heart Fail. 2020 Jul;22(7):1247-1258. doi: 10.1002/ejhf.1867. Epub 2020 Jun 15.
PMID: 32539224DERIVEDPetrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020 Apr 14;323(14):1353-1368. doi: 10.1001/jama.2020.1906.
PMID: 32219386DERIVEDKosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Kober L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjostrand M, Langkilde AM, McMurray JJV. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation. 2020 Jan 14;141(2):90-99. doi: 10.1161/CIRCULATIONAHA.119.044138. Epub 2019 Nov 17.
PMID: 31736335DERIVEDMartinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Ponikowski P, Sabatine MS, DeMets DL, Dutkiewicz-Piasecka M, Bengtsson O, Sjostrand M, Langkilde AM, Jhund PS, McMurray JJV. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. 2020 Jan 14;141(2):100-111. doi: 10.1161/CIRCULATIONAHA.119.044133. Epub 2019 Nov 17.
PMID: 31736328DERIVEDMcMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
PMID: 31535829DERIVEDMcMurray JJV, DeMets DL, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjostrand M, Solomon SD; DAPA-HF Committees and Investigators. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019 Nov;21(11):1402-1411. doi: 10.1002/ejhf.1548. Epub 2019 Jul 15.
PMID: 31309699DERIVEDNassif ME, Kosiborod M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes Metab. 2019 Apr;21 Suppl 2:19-23. doi: 10.1111/dom.13678.
PMID: 31081589DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- AstraZeneca Clinical Study Information Center
- Organization
- AstraZeneca
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 26, 2017
First Posted
January 30, 2017
Study Start
February 8, 2017
Primary Completion
July 17, 2019
Study Completion
July 17, 2019
Last Updated
September 1, 2020
Results First Posted
September 1, 2020
Record last verified: 2020-08